APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cardiometabolic Disease Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cardiometabolic Disease Drug Industry Research Report 2026

27 December 2025130 pages

Choose your research edition.

Industry ResearchCardiometabolic Disease Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Cardiometabolic Disease Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Cardiometabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cardiometabolic Disease Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Cardiometabolic Disease Drug Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Cardiometabolic Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cardiometabolic Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cardiometabolic Disease Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cardiometabolic Disease Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cardiometabolic Disease Drug include Qilu Pharmaceutical, Merck, Roche Holding AG, Chengda Pharmaceutical, ZMC, Taj Pharma, Sydler Group, Space Biology and Servier, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cardiometabolic Disease Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cardiometabolic Disease Drug Market by Company

Qilu Pharmaceutical

Merck

Roche Holding AG

Chengda Pharmaceutical

ZMC

Taj Pharma

Sydler Group

Space Biology

Servier

Northeast Pharmaceutical

NHU

Lonza Group

Kingdomway

Kaneka

Hengtai Chemical

Biosint

Abbott

Cardiometabolic Disease Drug Segment by Type

Coenzyme Q10

Cyclic Adenosine Monophosphate

Trimetazidine

L-carnitine

Others

Cardiometabolic Disease Drug Segment by Application

Retail Pharmacy

Online Sales

Hospital

Clinic

Others

Cardiometabolic Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiometabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cardiometabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiometabolic Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cardiometabolic Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cardiometabolic Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cardiometabolic Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cardiometabolic Disease Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cardiometabolic Disease Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cardiometabolic Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cardiometabolic Disease Drug Revenue of Manufacturers (2021-2026) Table 9. Global Cardiometabolic Disease Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cardiometabolic Disease Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cardiometabolic Disease Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cardiometabolic Disease Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cardiometabolic Disease Drug, Product Type & Application Table 14. Global Cardiometabolic Disease Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cardiometabolic Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Qilu Pharmaceutical Company Information Table 19. Qilu Pharmaceutical Business Overview Table 20. Qilu Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 22. Qilu Pharmaceutical Recent Developments Table 23. Merck Company Information Table 24. Merck Business Overview Table 25. Merck Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Merck Cardiometabolic Disease Drug Product Portfolio Table 27. Merck Recent Developments Table 28. Roche Holding AG Company Information Table 29. Roche Holding AG Business Overview Table 30. Roche Holding AG Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Roche Holding AG Cardiometabolic Disease Drug Product Portfolio Table 32. Roche Holding AG Recent Developments Table 33. Chengda Pharmaceutical Company Information Table 34. Chengda Pharmaceutical Business Overview Table 35. Chengda Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 37. Chengda Pharmaceutical Recent Developments Table 38. ZMC Company Information Table 39. ZMC Business Overview Table 40. ZMC Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. ZMC Cardiometabolic Disease Drug Product Portfolio Table 42. ZMC Recent Developments Table 43. Taj Pharma Company Information Table 44. Taj Pharma Business Overview Table 45. Taj Pharma Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Taj Pharma Cardiometabolic Disease Drug Product Portfolio Table 47. Taj Pharma Recent Developments Table 48. Sydler Group Company Information Table 49. Sydler Group Business Overview Table 50. Sydler Group Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sydler Group Cardiometabolic Disease Drug Product Portfolio Table 52. Sydler Group Recent Developments Table 53. Space Biology Company Information Table 54. Space Biology Business Overview Table 55. Space Biology Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Space Biology Cardiometabolic Disease Drug Product Portfolio Table 57. Space Biology Recent Developments Table 58. Servier Company Information Table 59. Servier Business Overview Table 60. Servier Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Servier Cardiometabolic Disease Drug Product Portfolio Table 62. Servier Recent Developments Table 63. Northeast Pharmaceutical Company Information Table 64. Northeast Pharmaceutical Business Overview Table 65. Northeast Pharmaceutical Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolio Table 67. Northeast Pharmaceutical Recent Developments Table 68. NHU Company Information Table 69. NHU Business Overview Table 70. NHU Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. NHU Cardiometabolic Disease Drug Product Portfolio Table 72. NHU Recent Developments Table 73. Lonza Group Company Information Table 74. Lonza Group Business Overview Table 75. Lonza Group Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Lonza Group Cardiometabolic Disease Drug Product Portfolio Table 77. Lonza Group Recent Developments Table 78. Kingdomway Company Information Table 79. Kingdomway Business Overview Table 80. Kingdomway Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Kingdomway Cardiometabolic Disease Drug Product Portfolio Table 82. Kingdomway Recent Developments Table 83. Kaneka Company Information Table 84. Kaneka Business Overview Table 85. Kaneka Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Kaneka Cardiometabolic Disease Drug Product Portfolio Table 87. Kaneka Recent Developments Table 88. Hengtai Chemical Company Information Table 89. Hengtai Chemical Business Overview Table 90. Hengtai Chemical Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hengtai Chemical Cardiometabolic Disease Drug Product Portfolio Table 92. Hengtai Chemical Recent Developments Table 93. Biosint Company Information Table 94. Biosint Business Overview Table 95. Biosint Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Biosint Cardiometabolic Disease Drug Product Portfolio Table 97. Biosint Recent Developments Table 98. Abbott Company Information Table 99. Abbott Business Overview Table 100. Abbott Cardiometabolic Disease Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Abbott Cardiometabolic Disease Drug Product Portfolio Table 102. Abbott Recent Developments Table 103. Global Cardiometabolic Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Cardiometabolic Disease Drug Sales by Region (2021-2026) & (K Units) Table 105. Global Cardiometabolic Disease Drug Sales Market Share by Region (2021-2026) Table 106. Global Cardiometabolic Disease Drug Sales by Region (2027-2032) & (K Units) Table 107. Global Cardiometabolic Disease Drug Sales Market Share by Region (2027-2032) Table 108. Global Cardiometabolic Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Cardiometabolic Disease Drug Revenue Market Share by Region (2021-2026) Table 110. Global Cardiometabolic Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Cardiometabolic Disease Drug Revenue Market Share by Region (2027-2032) Table 112. North America Cardiometabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 114. North America Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 115. North America Cardiometabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Cardiometabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Cardiometabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 119. Europe Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 120. Europe Cardiometabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Cardiometabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Cardiometabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific Cardiometabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Cardiometabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Cardiometabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 129. South America Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 130. South America Cardiometabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Cardiometabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Cardiometabolic Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa Cardiometabolic Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Cardiometabolic Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Cardiometabolic Disease Drug Sales by Type (2021-2026) & (K Units) Table 138. Global Cardiometabolic Disease Drug Sales by Type (2027-2032) & (K Units) Table 139. Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2026) Table 140. Global Cardiometabolic Disease Drug Sales Market Share by Type (2027-2032) Table 141. Global Cardiometabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Cardiometabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2026) Table 144. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2027-2032) Table 145. Global Cardiometabolic Disease Drug Price by Type (2021-2026) & (US$/Unit) Table 146. Global Cardiometabolic Disease Drug Price by Type (2027-2032) & (US$/Unit) Table 147. Global Cardiometabolic Disease Drug Sales by Application (2021-2026) & (K Units) Table 148. Global Cardiometabolic Disease Drug Sales by Application (2027-2032) & (K Units) Table 149. Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2026) Table 150. Global Cardiometabolic Disease Drug Sales Market Share by Application (2027-2032) Table 151. Global Cardiometabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Cardiometabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2026) Table 154. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2027-2032) Table 155. Global Cardiometabolic Disease Drug Price by Application (2021-2026) & (US$/Unit) Table 156. Global Cardiometabolic Disease Drug Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Cardiometabolic Disease Drug Distributors List Table 160. Cardiometabolic Disease Drug Customers List Table 161. Cardiometabolic Disease Drug Industry Trends Table 162. Cardiometabolic Disease Drug Industry Drivers Table 163. Cardiometabolic Disease Drug Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cardiometabolic Disease Drug Product Image Figure 5. Global Cardiometabolic Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cardiometabolic Disease Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Cardiometabolic Disease Drug Sales (2021-2032) & (K Units) Figure 8. Global Cardiometabolic Disease Drug Average Price (US$/Unit) & (2021-2032) Figure 9. Coenzyme Q10 Product Image Figure 10. Cyclic Adenosine Monophosphate Product Image Figure 11. Trimetazidine Product Image Figure 12. L-carnitine Product Image Figure 13. Others Product Image Figure 14. Retail Pharmacy Product Image Figure 15. Online Sales Product Image Figure 16. Hospital Product Image Figure 17. Clinic Product Image Figure 18. Others Product Image Figure 19. Global Cardiometabolic Disease Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Cardiometabolic Disease Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Cardiometabolic Disease Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Cardiometabolic Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Cardiometabolic Disease Drug Sales by Region in 2025 Figure 25. Global Cardiometabolic Disease Drug Revenue by Region in 2025 Figure 26. North America Cardiometabolic Disease Drug Market Size by Country in 2025 Figure 27. North America Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 28. North America Cardiometabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Cardiometabolic Disease Drug Market Size by Country in 2025 Figure 33. Europe Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Cardiometabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Cardiometabolic Disease Drug Market Size by Country in 2025 Figure 46. Asia Pacific Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Cardiometabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 48. China Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Cardiometabolic Disease Drug Market Size by Country in 2025 Figure 57. South America Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 58. South America Cardiometabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Cardiometabolic Disease Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Cardiometabolic Disease Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Cardiometabolic Disease Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Cardiometabolic Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2032) Figure 71. Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Cardiometabolic Disease Drug Price (US$/Unit) by Type (2021-2032) Figure 73. Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2032) Figure 74. Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Cardiometabolic Disease Drug Price (US$/Unit) by Application (2021-2032) Figure 76. Cardiometabolic Disease Drug Value Chain Figure 77. Cardiometabolic Disease Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Cardiometabolic Disease Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Coenzyme Q10
  • Cyclic Adenosine Monophosphate
  • Trimetazidine
  • L-carnitine
  • Others
Applications
  • Retail Pharmacy
  • Online Sales
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • Merck
  • Roche Holding AG
  • Chengda Pharmaceutical
  • ZMC
  • Taj Pharma
  • Sydler Group
  • Space Biology
  • Servier
  • Northeast Pharmaceutical
  • NHU
  • Lonza Group
  • Kingdomway
  • Kaneka
  • Hengtai Chemical
  • Biosint
  • Abbott

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cardiometabolic Disease Drug Market Size (2021-2032)
  4. 2.2.2 Global Cardiometabolic Disease Drug Sales (2021-2032)
  5. 2.2.3 Global Cardiometabolic Disease Drug Market Average Price (2021-2032)
  6. 2.3 Cardiometabolic Disease Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Coenzyme Q10
  9. 2.3.3 Cyclic Adenosine Monophosphate
  10. 2.3.4 Trimetazidine
  11. 2.3.5 L-carnitine
  12. 2.3.6 Others
  13. 2.4 Cardiometabolic Disease Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Retail Pharmacy
  16. 2.4.3 Online Sales
  17. 2.4.4 Hospital
  18. 2.4.5 Clinic
  19. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cardiometabolic Disease Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cardiometabolic Disease Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cardiometabolic Disease Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cardiometabolic Disease Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cardiometabolic Disease Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cardiometabolic Disease Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cardiometabolic Disease Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Cardiometabolic Disease Drug, Established Date
  9. 3.9 Global Cardiometabolic Disease Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Qilu Pharmaceutical
  2. 4.1.1 Qilu Pharmaceutical Company Information
  3. 4.1.2 Qilu Pharmaceutical Business Overview
  4. 4.1.3 Qilu Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Qilu Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  6. 4.1.5 Qilu Pharmaceutical Recent Developments
  7. 4.2 Merck
  8. 4.2.1 Merck Company Information
  9. 4.2.2 Merck Business Overview
  10. 4.2.3 Merck Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Merck Cardiometabolic Disease Drug Product Portfolio
  12. 4.2.5 Merck Recent Developments
  13. 4.3 Roche Holding AG
  14. 4.3.1 Roche Holding AG Company Information
  15. 4.3.2 Roche Holding AG Business Overview
  16. 4.3.3 Roche Holding AG Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Roche Holding AG Cardiometabolic Disease Drug Product Portfolio
  18. 4.3.5 Roche Holding AG Recent Developments
  19. 4.4 Chengda Pharmaceutical
  20. 4.4.1 Chengda Pharmaceutical Company Information
  21. 4.4.2 Chengda Pharmaceutical Business Overview
  22. 4.4.3 Chengda Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Chengda Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  24. 4.4.5 Chengda Pharmaceutical Recent Developments
  25. 4.5 ZMC
  26. 4.5.1 ZMC Company Information
  27. 4.5.2 ZMC Business Overview
  28. 4.5.3 ZMC Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 ZMC Cardiometabolic Disease Drug Product Portfolio
  30. 4.5.5 ZMC Recent Developments
  31. 4.6 Taj Pharma
  32. 4.6.1 Taj Pharma Company Information
  33. 4.6.2 Taj Pharma Business Overview
  34. 4.6.3 Taj Pharma Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Taj Pharma Cardiometabolic Disease Drug Product Portfolio
  36. 4.6.5 Taj Pharma Recent Developments
  37. 4.7 Sydler Group
  38. 4.7.1 Sydler Group Company Information
  39. 4.7.2 Sydler Group Business Overview
  40. 4.7.3 Sydler Group Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sydler Group Cardiometabolic Disease Drug Product Portfolio
  42. 4.7.5 Sydler Group Recent Developments
  43. 4.8 Space Biology
  44. 4.8.1 Space Biology Company Information
  45. 4.8.2 Space Biology Business Overview
  46. 4.8.3 Space Biology Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Space Biology Cardiometabolic Disease Drug Product Portfolio
  48. 4.8.5 Space Biology Recent Developments
  49. 4.9 Servier
  50. 4.9.1 Servier Company Information
  51. 4.9.2 Servier Business Overview
  52. 4.9.3 Servier Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Servier Cardiometabolic Disease Drug Product Portfolio
  54. 4.9.5 Servier Recent Developments
  55. 4.10 Northeast Pharmaceutical
  56. 4.10.1 Northeast Pharmaceutical Company Information
  57. 4.10.2 Northeast Pharmaceutical Business Overview
  58. 4.10.3 Northeast Pharmaceutical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Northeast Pharmaceutical Cardiometabolic Disease Drug Product Portfolio
  60. 4.10.5 Northeast Pharmaceutical Recent Developments
  61. 4.11 NHU
  62. 4.11.1 NHU Company Information
  63. 4.11.2 NHU Business Overview
  64. 4.11.3 NHU Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 NHU Cardiometabolic Disease Drug Product Portfolio
  66. 4.11.5 NHU Recent Developments
  67. 4.12 Lonza Group
  68. 4.12.1 Lonza Group Company Information
  69. 4.12.2 Lonza Group Business Overview
  70. 4.12.3 Lonza Group Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Lonza Group Cardiometabolic Disease Drug Product Portfolio
  72. 4.12.5 Lonza Group Recent Developments
  73. 4.13 Kingdomway
  74. 4.13.1 Kingdomway Company Information
  75. 4.13.2 Kingdomway Business Overview
  76. 4.13.3 Kingdomway Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Kingdomway Cardiometabolic Disease Drug Product Portfolio
  78. 4.13.5 Kingdomway Recent Developments
  79. 4.14 Kaneka
  80. 4.14.1 Kaneka Company Information
  81. 4.14.2 Kaneka Business Overview
  82. 4.14.3 Kaneka Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Kaneka Cardiometabolic Disease Drug Product Portfolio
  84. 4.14.5 Kaneka Recent Developments
  85. 4.15 Hengtai Chemical
  86. 4.15.1 Hengtai Chemical Company Information
  87. 4.15.2 Hengtai Chemical Business Overview
  88. 4.15.3 Hengtai Chemical Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Hengtai Chemical Cardiometabolic Disease Drug Product Portfolio
  90. 4.15.5 Hengtai Chemical Recent Developments
  91. 4.16 Biosint
  92. 4.16.1 Biosint Company Information
  93. 4.16.2 Biosint Business Overview
  94. 4.16.3 Biosint Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Biosint Cardiometabolic Disease Drug Product Portfolio
  96. 4.16.5 Biosint Recent Developments
  97. 4.17 Abbott
  98. 4.17.1 Abbott Company Information
  99. 4.17.2 Abbott Business Overview
  100. 4.17.3 Abbott Cardiometabolic Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Abbott Cardiometabolic Disease Drug Product Portfolio
  102. 4.17.5 Abbott Recent Developments
5 Global Cardiometabolic Disease Drug Market Scenario by Region
  1. 5.1 Global Cardiometabolic Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cardiometabolic Disease Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Cardiometabolic Disease Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Cardiometabolic Disease Drug Sales by Region: 2027-2032
  5. 5.3 Global Cardiometabolic Disease Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Cardiometabolic Disease Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Cardiometabolic Disease Drug Revenue by Region: 2027-2032
  8. 5.4 North America Cardiometabolic Disease Drug Market Facts & Figures by Country
  9. 5.4.1 North America Cardiometabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cardiometabolic Disease Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Cardiometabolic Disease Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Cardiometabolic Disease Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Cardiometabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Cardiometabolic Disease Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Cardiometabolic Disease Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Cardiometabolic Disease Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Cardiometabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Cardiometabolic Disease Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Cardiometabolic Disease Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Cardiometabolic Disease Drug Market Facts & Figures by Country
  41. 5.7.1 South America Cardiometabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Cardiometabolic Disease Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Cardiometabolic Disease Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Cardiometabolic Disease Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Cardiometabolic Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Cardiometabolic Disease Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Cardiometabolic Disease Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Cardiometabolic Disease Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Cardiometabolic Disease Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cardiometabolic Disease Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cardiometabolic Disease Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Cardiometabolic Disease Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cardiometabolic Disease Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cardiometabolic Disease Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cardiometabolic Disease Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Cardiometabolic Disease Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cardiometabolic Disease Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cardiometabolic Disease Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Cardiometabolic Disease Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cardiometabolic Disease Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cardiometabolic Disease Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cardiometabolic Disease Drug Value Chain Analysis
  2. 8.1.1 Cardiometabolic Disease Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cardiometabolic Disease Drug Production Mode & Process
  5. 8.2 Cardiometabolic Disease Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cardiometabolic Disease Drug Distributors
  8. 8.2.3 Cardiometabolic Disease Drug Customers
9 Global Cardiometabolic Disease Drug Analyzing Market Dynamics
  1. 9.1 Cardiometabolic Disease Drug Industry Trends
  2. 9.2 Cardiometabolic Disease Drug Industry Drivers
  3. 9.3 Cardiometabolic Disease Drug Industry Opportunities and Challenges
  4. 9.4 Cardiometabolic Disease Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst